Elicio Therapeutics financials
$1.84−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$10.4M | -$10.6M | -$8.8M | -$8.0M | -$10.1M | -$10.7M | -$13.5M | -$10.3M | -$10.9M | -$10.2M | -$9.4M | -$10.8M |
| Net income | -$8.2M | -$11.8M | -$7.7M | -$10.1M | -$10.6M | -$11.2M | -$14.0M | -$18.8M | -$7.2M | -$11.8M | -$8.9M | -$10.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.43 | $-0.65 | $-0.50 | $-0.60 | $-0.66 | $-0.87 | $-1.02 | $-1.39 | $-0.64 | $-1.15 | $-1.04 | $-1.27 |
| EBITDA | -$10.4M | -$10.6M | -$8.8M | -$8.0M | -$10.0M | -$10.7M | -$13.4M | -$10.3M | -$10.8M | -$10.2M | -$9.3M | -$10.7M |
| Operating cash flow | -$8.2M | -$11.6M | -$6.8M | -$11.1M | -$8.9M | -$10.1M | -$8.7M | -$7.3M | -$8.9M | -$12.1M | -$9.9M | -$5.2M |
| Free cash flow | -$8.2M | -$11.6M | -$6.8M | -$11.1M | -$8.9M | -$10.1M | -$8.8M | -$7.3M | -$9.0M | -$12.1M | -$9.9M | -$5.2M |
| Diluted shares | 19.2M | 18.2M | 15.5M | 16.7M | 16.1M | 13.0M | 13.7M | 13.6M | 11.3M | 10.3M | 8.6M | 8.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $23.5M | $14.9M | $18.6M | $20.6M | $22.1M | $18.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $9.5M | $9.5M | $9.4M | $9.7M | $9.3M | $0.00 |
| Total assets | $31.3M | $22.7M | $25.9M | $28.3M | $29.5M | $28.1M |
| Total liabilities | $23.4M | $24.1M | $24.2M | $24.5M | $27.7M | $19.2M |
| Shareholders' equity | $7.9M | -$1.4M | $1.6M | $3.8M | $1.8M | $8.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology